Press Releases

Date Title and Summary Additional Formats
Toggle Summary Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development
SAN FRANCISCO , April 22, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Steven J.
View HTML
Toggle Summary Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
- Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference call Monday, April 15, 2019 at 8am EDT SAN FRANCISCO , April 13, 2019 (GLOBE
View HTML
Toggle Summary Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV cccDNA shown to have a limited half-life, suggesting potential for curative treatment regimen Interim data from Phase 2a
View HTML
Toggle Summary Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
SAN FRANCISCO , March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the acceptance of oral and poster
View HTML
Toggle Summary Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit
SAN FRANCISCO , March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Derek Small , Assembly’s
View HTML
Toggle Summary Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
SAN FRANCISCO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the fourth
View HTML
Toggle Summary Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus
Interim results anticipated in Q2 of 2019 SAN FRANCISCO , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today
View HTML
Toggle Summary Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD
First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and
View HTML
Toggle Summary Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update
ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate SAN FRANCISCO , Nov. 08, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc.
View HTML
Toggle Summary Assembly Biosciences Announces November Conference Participation
SAN FRANCISCO , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at various upcoming
View HTML